ArticleImmunity, inflammation and disease2025
Immunoglobulin G4 Smoldering Multiple Myeloma With Immunoglobulin G4-Related Autoimmune Hepatitis: A Rare Case Report.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMultiple myeloma (MM) is a common malignant tumor of the hematological system caused by the malignant proliferation of plasma cells, characterized by the production of M proteins and CRAB symptoms. Among them, the Immunoglobulin G MM is the most common, while the IgG4-MM is extremely rare. Smoldering multiple myeloma refers to a state where there are no clinical symptoms. However, bone marrow plasma cell infiltration reaches 10%-59%, and previously, there were no reports of Immunoglobulin G4 smoldering multiple myeloma (IgG4 SMM) internationally. CASE PRESENTATION: An over-50-year-old woman visited the hospital due to abnormal liver function. Laboratory tests showed a significant increase in serum IgG4 (24.95 g/L), and serum protein electrophoresis detected IgG-κ M protein (16.05 g/L). A liver biopsy showed IgG4 + plasma cell infiltration (11/HPF) and interface hepatitis. Bone marrow biopsy confirmed IgG4 monoclonal plasma cell proliferation. The diagnosis was IgG4-κ SMM combined with Immunoglobulin G4-related autoimmune hepatitis (IgG4-AIH) and primary biliary cholangitis (PBC). The patient had no typical CRAB symptoms, and no osteolytic destruction was found in imaging. So we formulated a chemotherapy regimen using Bortezomib and dexamethasone, combined with azathioprine for immunomodulation. Unfortunately, after one session of chemotherapy, the patient did not return to the hospital for further evaluation.
conclusionThis article explores the clinical features and diagnostic challenges of IgG4 SMM coexisting with IgG4-AIH. IgG4 type SMM needs to be identified with IgG4-RD. Clinicians should pay attention to IgG subtype detection and clonal plasma cell analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.